Camp4 Therapeutics Corp (CAMP) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$4.03

From 52W high−40.53%

Volume1.04M

Market cap$266.07M

P/E (TTM)—

P/S (TTM)63.1x

Div yield—

Key dataSep 18, 2026

Open

$4.03

From 52W high

−40.53%

Volume

1.04M

Market cap

$266.07M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−2.5x

P/E (TTM)

—

RSI (14)

45.9

MomentumView details →

1D Return

+5.21%

YTD Return

−34.18%

SummaryUpdated Jun 1, 2026

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) is a biotechnology company founded in 2015 by renowned scientists Richard A. Young and Leonard Zon, headquartered in Cambridge, Massachusetts. The company went public in October 2024 through an initial public offering. CAMP4 operates as a clinical-stage biotechnology company focused on discovering and developing novel treatment options for patients with serious diseases through its proprietary regulatory RNA platform technology.

Ask drillr about Camp4 Therapeutics Corp →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−2.5x

EV/Sales

43.0x

P/S (TTM)

63.1x

P/B (TTM)

−383.9x

ProfitabilityView details →

Gross Margin

77.80%

Net Margin

−2543.74%

EBITDA Margin

−1735.48%

ROE (TTM)

—

ROA (TTM)

−114.79%

Asset Turnover

0.04x

GrowthView details →

Revenue YoY

+40.21%

EPS YoY

+15.21%

FCF YoY

+37.77%

Revenue CAGR 3Y

−77.20%

EPS CAGR 3Y

+0.38%

EBITDA YoY

−40.73%

MomentumView details →

1D Return

+5.21%

YTD Return

−34.18%

1Y Return

+76.97%

RSI (14)

45.9

vs 50D SMA

−1.48%

vs 200D SMA

−10.59%

Capital & dividendView details →

Debt/Equity

−3.42x

Current Ratio

4.70x

Quick Ratio

4.70x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.58

EPS Surprise

−174.32%

Beats (12Q)

3/12

Next Q EPS Est

−$0.17

Avg Surprise (4Q)

−81.91%

Rev Surprise

9.81%

Financials snapshotView financials →

Revenue (TTM)

4.22M

Net Income (TTM)

−107.24M

Op. CF (TTM)

−28.59M

Latest newsMore news →

The UK's Medicines and Healthcare products Regulatory Agency authorized CAMP4 Therapeutics to conduct a Phase 1/2 human clinical trial of CMP-002 in patients with SYNGAP1-related disorder.10d ago

CAMP4 Therapeutics Corporation reported a Q2 2026 loss of $0.22 per share, beating the Zacks Consensus Estimate of a $0.24 loss and improving from a $0.62 loss a year earlier.38d ago

Similar companies

Cue Biopharma, Inc.CUE MacroGenics, Inc.MGNX Entrada Therapeutics, Inc.TRDA Sionna Therapeutics, Inc.SION Lyell Immunopharma, Inc.LYEL AC Immune S.A.ACIU Find similar companies →

Latest newsMore news →

The UK's Medicines and Healthcare products Regulatory Agency authorized CAMP4 Therapeutics to conduct a Phase 1/2 human clinical trial of CMP-002 in patients with SYNGAP1-related disorder.10d ago CAMP4 Therapeutics Corporation reported a Q2 2026 loss of $0.22 per share, beating the Zacks Consensus Estimate of a $0.24 loss and improving from a $0.62 loss a year earlier.38d ago